COVID-19 heath crisis globally has infected over thirty-five million people and claimed more than a million lives across the globe, just in less than one year of its arrival. This is an escalating and unprecedented crisis that has never been witnessed at a global scale and calls for drastic measures to be taken in real-time. An immediate need for addressing this crisis includes building therapeutics to counter the virus.
At present, there are no FDA approved antivirals or vaccines for coronaviruses such as SARS-CoV and MERS that can be tried against novel SARS-CoV-2. The development of SARS-CoV-2 vaccine would require 12-18 months. Current treatment strategies are, therefore, focused on repurposing of already approved drugs for off-label use, notably broad-spectrum antivirals. Due to the enormity of COVID-19 pandemic and non-availability of any tested therapeutic option, there is an urgent need to rapidly develop pharmaceutical countermeasures against SARS-CoV-2.